SCHEMBL20161431

SCHEMBL20161431

O=C(O)CC1O[C@H](CO)[C@@H](OC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF2R P11717 2/20 0.55
LGALS3 P17931 3/20 0.54
LGALS8 O00214 2/20 0.54
LGALS4 P56470 2/20 0.54
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
FGF1 P05230 1/20 0.46
FGF2 P09038 1/20 0.46
VEGFA P15692 1/20 0.46
HPSE Q9Y251 1/20 0.46
TYR P14679 2/20 0.46
AMY1A P0DUB6 1/20 0.45
PTPN1 P18031 1/20 0.45
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
AMY2A P04746 1/20 0.44
LGALS9 O00182 1/20 0.44
LGALS1 P09382 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9208789 0.93 IGF2R (0.51) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL9216351 0.90 LGALS8 (0.51) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL13515800 0.89 LGALS8 (0.64) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL12756242 0.89 LGALS8 (0.64) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL17468102 0.89 LGALS8 (0.64) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL21391535 0.88 LGALS3 (0.52) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL22906100 0.88 LGALS3 (0.52) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL21391439 0.88 LGALS3 (0.52) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL21391458 0.88 LGALS3 (0.52) IGF2RLGALS3LGALS8LGALS4MEN1
SCHEMBL21391506 0.88 LGALS3 (0.52) IGF2RLGALS3LGALS8LGALS4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11045411-B2 Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same L'OREAL (FR) 2021-06-29 US disclosed
US-20180133137-A1 PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME L'OREAL (FR) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133137-A1 PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME KRT18, CUTA, GLA IGF2R 1514/4885LGALS3 403/4885LGALS8 270/4885
US-11045411-B2 Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same KRT18, CUTA, GLA IGF2R 1514/4885LGALS3 403/4885LGALS8 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.